Tianjin Medical University was founded in 1951; was the first medical institution approved by the State Council of the People's Republic of China. Hsien-I Chu, a renowned endocrinologist, was the first president of the university. The current president is Yongfeng Shang.In December 1993, with the approval of the State Education Council, the Tianjin Medical College and the Tianjin Second Medical College were integrated into the Tianjin Medical University. In December 1996, the university was accepted into Project 211, so it became one of the 97 key institutions in which there are 9 medical institutions that will be constructed emphatically by the State.In 1981, the university was approved by the Academic Degree Committee of State Council to confer the Doctorate Degree, Master's Degree and Bachelor's Degree and in 1988, was permitted to set up seven-year medical program.It is listed in International Medical Education Directory . Wikipedia.
Yang J.,Tianjin Medical University |
Zhang W.,University of Houston
Current Opinion in Oncology | Year: 2013
PURPOSE OF REVIEW: Recent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets. RECENT FINDINGS: The genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-α/β, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-κB ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets. SUMMARY: These translational studies in osteosarcoma have identified new molecular targets for osteosarcoma. Copyright © Lippincott Williams & Wilkins.
Zhang C.,Tianjin Medical University |
Zhang C.,CAS Research Center for Eco Environmental Sciences
Oncogene | Year: 2014
Rho-associated kinase (ROCK) has an essential role in governing cell morphology and motility, and increased ROCK activity contributes to cancer cell invasion and metastasis. Burgeoning data suggest that ROCK is also involved in the growth regulation of tumor cells. However, thus far, the molecular mechanisms responsible for ROCK-governed tumor cell growth have not been clearly elucidated. Here we showed that inhibition of ROCK kinase activity, either by a selective ROCK inhibitor Y27632 or by specific ROCK small interfering RNA (siRNA) molecules, attenuated not only motility but also the proliferation of PC3 prostate cancer cells in vitro and in vivo. Importantly, mechanistic investigation revealed that ROCK endowed cancer cells with tumorigenic capability, mainly by targeting c-Myc. ROCK could increase the transcriptional activity of c-Myc by promoting c-Myc protein stability, and ROCK inhibition reduced c-Myc-mediated expression of mRNA targets (such as HSPC111) and microRNA targets (such as miR-17-92 cluster). We provided evidence demonstrating that ROCK1 directly interacted with and phosphorylated c-Myc, resulting in stabilization of the protein and activation of its transcriptional activity. Suppression of ROCK-c-Myc downstream molecules, such as c-Myc-regulated miR-17, also impaired tumor cell growth in vitro and in vivo. In addition, c-Myc was shown to exert a positive feedback regulation on ROCK by increasing RhoA mRNA expression. Therefore, inhibition of ROCK and its stimulated signaling might prove to be a promising strategy for restraining tumor progression in prostate cancer.
Li Y.,Tianjin Medical University
Journal of neurosurgery | Year: 2012
The goal of this study was to assess neuroimaging and clinical outcomes in patients harboring brainstem metastases that were treated with the Leksell Gamma Knife. Twenty-eight patients with brainstem metastases (32 lesions: 8 midbrain, 21 pontine, and 3 medullary) were consecutively treated with GKS. The primary cancer diagnoses in this group included 22 cases of lung cancer, 5 cases of breast cancer, and 1 case of rectal cancer. The median age of the patients was 61 years (range 45-83 years). The median treated lesion volume was 0.78 cm(3) (range 0.03-5.6 cm(3)), and the median GKS margin dose was 16 Gy (range 12-20 Gy). Overall survival in these patients was calculated using the Kaplan-Meier method. The median survival time was 9 months after GKS (range 2-32 months). Survival was 39.3% at 1 year and 10.7% at 2 years. The tumor control rate in the series was 90.6% (29 of 32 lesions). Development of peritumoral edema occurred in 1 patient after GKS; 4 months after GKS, the edema disappeared. Gamma Knife surgery using a median margin dose of 16 Gy is a safe and effective local therapy for patients with brainstem metastases.
Wang X.,Tianjin Medical University
British Journal of Cancer | Year: 2014
Background:Syndecan-1 (Sdc-1) shedding induced by matrix metalloproteinase-7 (MMP-7) and additional proteases has an important role in cancer development. However, the impact of Sdc-1 shedding on chemotherapeutic resistance has not been reported.Methods:We examined Sdc-1 shedding in colorectal cancer by enzyme-linked immunosorbent assay (ELISA), Dot blot, reverse transcription-PCR (RT-PCR), immunohistochemistry and so on, its impact on chemotherapeutic sensitivity by collagen gel droplet embedded culture-drug sensitivity test (CD-DST) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and potential mechanisms of action by Dot blot, western blot and immunofluorescence.Results:Sdc-1 shedding was increased in colorectal cancer patients, Sdc-1 serum levels in postoperative patients were lower than in preoperative patients, but still higher than those observed in healthy adults. Patients with high preoperative Sdc-1 serum levels were less responsive to 5-Fluorouracil, Oxaliplatin, Irintecan, Cisplatin or Paclitaxel chemotherapy. Moreover, the disease-free survival of patients with high preoperative Sdc-1 serum levels was significantly poorer. The possible mechanism of chemotherapy resistance in colorectal cancer can be attributed to Sdc-1 shedding, which enhances EGFR phosphorylation and downstream signalling.Conclusions:Shed Sdc-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer, and Sdc-1 serum levels could be a new prognostic marker in colorectal cancer.British Journal of Cancer advance online publication, 16 October 2014; doi:10.1038/bjc.2014.493 www.bjcancer.com. © 2014 Cancer Research UK
Wang W.,Tianjin Medical University
Journal of experimental & clinical cancer research : CR | Year: 2010
BACKGROUND: Survival of laryngeal squamous cell carcinoma (LSCC) patients has remained unchanged over recent years due to its uncontrolled recurrence and local lymph node metastasis. Vasculogenic mimicry (VM) is an alternative type of blood supplement related to more aggressive tumor biology and increased tumor-related mortality. This study aimed to investigate the unique role of VM in the progression of LSCC. METHODS: We reviewed clinical pathological data of 203 cases of LSCC both prospectively and retrospectively. VM and endothelium-dependent vessel (EDV) were detected by immunohistochemistry and double staining to compare their different clinical pathological significance in LSCC. Survival analyses were performed to assess their prognostic significance as well. RESULTS: Both VM and EDV existed in LSCC type of blood supply. VM is related to pTNM stage, lymph node metastasis and pathology grade. In contrust, EDV related to location, pTNM stage, T stage and distant metastasis. Univariate analysis showed VM, pTNM stage, T classification, nodal status, histopathological grade, tumor size, and radiotherapy to be related to overall survival (OS). While, VM, location, tumor size and radiotherapy were found to relate to disease free survival (DFS). Multivariate analysis indicated that VM, but not EDV, was an adverse predictor for both OS and DFS. CONCLUSIONS: VM existed in LSCC. It contributed to the progression of LSCC by promoting lymph node metastasis. It is an independent predictors of a poor prognosis of LSCC.
Gao Y.,Tianjin Medical University
International journal of nanomedicine | Year: 2011
RNA interference is a powerful method for the knockdown of pathologically relevant genes. Small interfering RNAs (siRNAs) have been widely demonstrated as effective biomedical genetic-therapy applications for many diseases. Unfortunately, siRNA duplexes are not ideal drug-like molecules. Problems hindering their effective application fundamentally lie in their delivery, stability, and off-target effects. Delivery systems provide solutions to many of the challenges facing siRNA therapeutics. Due to some fatal disadvantages of viral vectors, nonviral carriers have been studied extensively. Aside from liposomes, nanoparticles and cationic polymer carriers have exhibited improved in vivo stability, better biocompatibility, and efficiency for gene silencing with less cellular toxicity. They may represent a promising strategy for siRNA-based therapies, especially as nanomaterials. The present review also summarizes other methods of siRNA delivery and the side effects of the nanoparticles.
Liu X.,Tianjin Medical University
Journal of neurosurgery | Year: 2012
The goal of this study was to evaluate the efficacy and safety of same-day stereotactic aspiration and Gamma knife surgery (GKS) for cystic intracranial tumors. Between 1996 and 2007, 77 patients harboring cystic intracranial tumors underwent a same-day procedure of MRI-guided cyst aspiration followed by GKS. The diagnoses were metastatic tumor in 43 patients, glial tumor in 12 patients, vestibular schwannoma in 10 patients, craniopharyngioma in 9 patients, and hemangioblastoma in 3 patients. An improvement in symptoms was achieved in 68 patients (88.3%) immediately after cyst aspiration. The mean tumor volume in this group of patients was 25.1 cm(3) before aspiration and 11.1 cm(3) afterward. Hemorrhage during the course of aspiration was encountered in 1 patient. Transient nausea after cyst aspiration developed in 3 patients. There was no treatment-related hematoma, seizure, neurological deficit, or infection. The median follow-up period was 16 months (range 6-108 months). Tumor control was achieved in 50 (80.6%) of 62 patients who participated in follow-up for at least 6 months. The same-day stereotactic aspiration and GKS procedure was safe in patients with cystic brain tumors. Prompt symptom relief was obtained after cyst aspiration. The decrease in tumor volume following aspiration made GKS more effective because a higher prescription dose could be administered with a lower possibility of radiation-induced side effects.
Wang Y.,Tianjin Medical University |
Shang Y.,Tianjin Medical University
Experimental Cell Research | Year: 2013
Epithelial-mesenchymal transition (EMT) is vital for morphogenesis during embryonic development and is also critical for the conversion of early stage tumors into invasive malignancies. Several key inducers of EMT are transcription factors that repress the expression of E-cadherin, whose loss is a hallmark of EMT. Epigenetic regulation encompasses three types of changes: DNA methylation, histone modifications, and microRNAs, each of which has been shown to play a key role in controlling epithelial-mesenchymal transition and cancer metastasis. As we gain deeper understanding of epigenetic mechanisms controlling EMT processes and orchestrating all the metastatic steps, we broaden the therapeutic potentials of epigenetic drugs, such as DNA demethylating drugs and histone deacetylase/demethylase inhibitors, which can act upon metastasis-related genes, restoring their expression and biological functions. © 2012 Elsevier Inc.
Hao J.,Tianjin Medical University
OncoImmunology | Year: 2015
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal digestive tract malignancies. Hypoxia-inducible factor (HIF-1) is over-expressed in pancreatic cancer and associated with poor prognosis. During the past several years, we focused on identifying the function of HIF-1 and the antitumor effect of HIF-1 inhibitors on PDAC, especially in regards to immunogenic cell death. © 2015 Taylor & Francis Group, LLC.
Wei S.,Tianjin Medical University |
Wang Y.,Tianjin Medical University
Graefe's Archive for Clinical and Experimental Ophthalmology | Year: 2013
Background: To compare the effect on corneal sensitivity between femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) and femtosecond lenticule extraction (ReLEx flex) or FS-LASIK and small-incision lenticule extraction (ReLEx smile) surgery. Methods: Twenty-seven subjects (54 eyes) underwent FS-LASIK, 22 subjects (40 eyes) underwent ReLEx flex, and 32 subjects (61 eyes) underwent ReLEx smile surgery. Cochet-Bonnet esthesiometry (Luneau Ophthalmologie Chartres, Cedex, France) was used to evaluate corneal sensitivity preoperatively as well as at 1 week and 1 and 3 months after surgery. Results: At 1 week, central, superior, nasal, and temporal corneal sensitivity in the ReLEx flex group was significantly higher than in the FS-LASIK group (P = 0.007, 0.004, 0.020, 0.004 respectively) and in the central and inferior areas at 3 months (P = 0.002, 0.009 respectively). A higher corneal sensitivity after ReLEx smile surgery was observed in every quadrant at 1 week and 1 and 3 months compared with FS-LASIK surgery (P < 0.01). Furthermore, in the ReLEx smile group, there were no statistical differences in the superior and temporal quadrants at 1 month postoperatively compared with preoperatively (5.19 ± 0.61 cm, P = 0.198 and 5.64 ± 0.48 cm, P = 0.330 respectively) and no significant differences in any quadrant at 3 months. Conclusions: Postoperative corneal sensitivity was not remarkably changed after ReLEx smile surgery compared with FS-LASIK. This might be because ReLEx is a flapless procedure. © 2013 Springer-Verlag Berlin Heidelberg.